Matthew B. Rettig, MD

Matthew Rettig, MD

Professor in Residence, Department of Medicine, Hematology/Oncology, Department of Urology
Medical Director, Prostate Cancer Program, UCLA Institute of Urologic Oncology
Chief, Division of Hematology-Oncology, Veterans Affairs Greater Los Angeles Healthcare System




Internal Medicine, Medical Oncology

Institutional Affiliation

Ronald Reagan UCLA Medical Center



Internal Medicine, UCLA School of Medicine, 1993 - 1996


Internal Medicine, LAC+USC Medical Center, 1990 - 1991


MD, Duke University School of Medicine, 1990


Internal Medicine, University of Washington School of Medicine, 1991 - 1993

Board Certifications

Medical Oncology, American Board of Internal Medicine, 1998
Internal Medicine, American Board of Internal Medicine, 1996

Contact Information

Scientific Interests

Dr. Matthew Rettig focuses on the management of genitourinary malignancies, with a clinical emphasis on advanced prostate cancer and a research emphasis on identifying biochemical targets for therapeutic translation in castration-resistant prostate cancer and clear cell renal cell carcinoma.

Highlighted Publications

An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther. 2007; 6(1): 61-9.

An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 2005; 25(17): 7546-56.

Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004; 64(2): 335-40.

An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003; 9(12): 4537-45.

An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003; 22(22): 3371-85.